Public Hearing on Expanded Access of Direct-Acting Antiviral Agents (DAAs) for the Treatment of Chronic Hepatitis C Infection in Patients with Unmet Medical Need

"The US Food & Drug Administration (FDA) is announcing a public hearing to obtain input on the scope and implementation of potential Expanded Access programs with Direct-Acting Antiviral Agents (DAAs) for treating chronic hepatitis C (CHC) infection in patients with unmet medical need."

Read more in FDA, March 26, 2010.

Note: The hearing is April 30.